To understand the full scope of a condition, pharma needs to appreciate the full tapestry of the patient experience. The challenge for industry in the realm of rare diseases, however, is to meaningfully engage with patients and convince them that they are an essential part of the research equation
As life sciences companies’ international ambitions grow, and global regulatory scrutiny in parallel, managing translated content is becoming ever more complex. So the promise of neural machine learning as a potential solution is appealing. But just how far can the technology go in reducing workloads and improving accuracy and turnaround times?